Latest stories on TVTX
Travere Therapeutics to Report Second Quarter 2026 Financial Results | TVTX Stock News
StockTitan50 · neutralgeneral
Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm
PR Newswire34 · bearishgeneral
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | TVTX Stock News
StockTitan50 · neutralgeneral
Travere Therapeutics plans accounting leadership transition in 2026
TipRanks50 · neutralgeneral
Travere Therapeutics, Inc. (TVTX) files 8-K
SEC 8-K50 · neutralgeneral
Travere Therapeutics: Filspari Is Becoming A Rare Kidney Disease Platform
Seeking Alpha67 · bullishproduct/pr
Travere Therapeutics Announces R&D Leadership Transition Plan
TipRanks50 · neutralgeneral
Travere Therapeutics, Inc. (TVTX) files 8-K
SEC 8-K50 · neutralgeneral
Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027 | TVTX Stock News
StockTitan50 · neutralgeneral
Is Travere Therapeutics, Inc. (TVTX) A Good Stock To Buy Now?
Yahoo Top57 · neutralanalyst
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | TVTX Stock News
StockTitan50 · neutralgeneral
Travere Therapeutics, Inc. (TVTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha56 · neutralgeneral
Travere inks licensing deal worth up to $1.1B with China’s Everest Medicines
Seeking Alpha63 · neutralm&a
Travere Licenses Civorebrutinib, Expands Kidney Disease Pipeline
TipRanks63 · neutralproduct/pr
Travere Shareholders Reinforce Governance and Compensation Framework
TipRanks50 · neutralgeneral
Travere Therapeutics Rides FILSPARI Surge After FDA Win
TipRanks73 · bullishproduct/pr